Leukaemia Cancer Chronic myeloid leukaemia
Conditions
Interventions
Cycle of chemotherapy and an autograft with subsequent IFN/IFN therapy alone
Sponsors
Medical Research Council (MRC) (UK)
Eligibility
Inclusion criteria
Inclusion criteria: 1. The interval from diagnosis to registration does not exceed 3 months (if received only hydroxyurea in these 3 months proceed to register, if alpha Interferon (IFN) has been given contact co-ordinators) 2. They are aged 18-60; they have newly diagnosed CML 3. They have acceptable criteria for chronic phase 4. They have given informed consent and are willing to be randomised, there is no contraindication to collection of blood or marrow progenitor cells before treatment is commenced 5. They are not pregnant
Exclusion criteria
Exclusion criteria: Not provided at time of registration
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Length of survival, quality of life, cytogenetic response | — |
Secondary
| Measure | Time frame |
|---|---|
| Not provided at time of registration | — |
Countries
United Kingdom
Outcome results
None listed